Related News
New drugs needed to tackle superbugs
Source: Agencies |
September 17, 2009, Thursday
|
Online Edition
Online Edition
EUROPEAN health agencies warn there are not enough new drugs under development to tackle the growing problem of superbugs in Europe.
In a joint report, the European Centre for Disease Control and the European Medicines Agency urge policy-makers to set up global and European strategies to address the problem of multidrug-resistant bacteria.
They say around 25,000 patients die in the European Union each year from antibiotic-resistant bacteria, which costs society 1.5 billion euro (US$2.2 billion) a year.
Today's report said only 15 new anti-bacterial drugs are under development, most of which are in very early stages.
MRSA, or methicillin-resistant Staphylococcus aureus, is the most common superbug, but others are increasing steadily.
In a joint report, the European Centre for Disease Control and the European Medicines Agency urge policy-makers to set up global and European strategies to address the problem of multidrug-resistant bacteria.
They say around 25,000 patients die in the European Union each year from antibiotic-resistant bacteria, which costs society 1.5 billion euro (US$2.2 billion) a year.
Today's report said only 15 new anti-bacterial drugs are under development, most of which are in very early stages.
MRSA, or methicillin-resistant Staphylococcus aureus, is the most common superbug, but others are increasing steadily.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
